Clarify Health
Value-based care analytics platform selling claims data and care workflow tools to payers and providers.
On the record
Checkpoint: Barclays-run sale process resolves, setting real recovery value for the preference stack
The call
Clarify built real data and workflow lock-in but is shrinking fast while a better-funded rival adds AI agents and wins the accounts Clarify needs to survive.
Clarify Health helps hospitals and health systems understand patient data from insurance claims to improve care and lower costs. The company built something hard to copy at first: a database of patient records over time, software that fits into doctors' workflows, and deals where they get paid based on results. But the company has lost about 70% of its staff since 2022, its value dropped 86%, and a competitor called Innovaccer is growing faster with more money and partnerships at seven of the top ten US hospital systems. Meanwhile, artificial intelligence is making it easier for anyone to analyze claims data, and Innovaccer is building AI tools that do some of Clarify's job automatically. The main thing to watch is whether Barclays can sell the company and whether its partnership with Loyal Health actually works in the next few quarters, because without a successful sale or partnership, the company's investors are unlikely to make money back.
Why
01
AI pressure: Innovaccer Population Health Copilot and Agents of Care. Innovaccer's AI agents wrap the same claims data into automated workflows, pulling health system contracts away from Clarify faster than it can rebuild pipeline. Could AI do the core job? Only partly.
02
Bigger players: Epic Systems and Oracle Health (HealthIntent). Epic covers roughly 35% of US hospitals and keeps building population health tools directly into the EHR, squeezing out standalone analytics vendors like Clarify. Could a giant copy it? Yes, easily.
03
What protects it. Longitudinal claims datasets and outcomes-based contracts already embedded in customer workflows, which are costly to rip out mid-contract.
What would change this call
Outcome of the Barclays-run sale process for Clarify Health. A low sale price would confirm the business lost most of its 2022 value.
Whether Clarify wins or loses a top-10 US health system contract against Innovaccer. Shows whether Clarify can still compete for large accounts or keeps losing them.
Headcount trend at Clarify Health over the next two quarters. Further declines would confirm continued contraction rather than stabilization.
Whether Clarify wins or loses a top-10 US health system contract against Innovaccer. Shows whether Clarify can still compete for large accounts or keeps losing them.
Headcount trend at Clarify Health over the next two quarters. Further declines would confirm continued contraction rather than stabilization.
Key numbers
- Valuation fell from $1.4B to ~$0.2B
- Headcount down to ~90 employees
- Innovaccer raised $275M at $3.45B valuation
Named risks
- Unresolved Barclays sale process with no confirmed outcome as of mid-2026.
- Headcount decline signals (~90 employees, -76 trajectory score) suggest active shrinkage.
- Valuation markdown estimate of ~86% from $1.4B 2022 peak to ~$0.2B mid-2026.
- Loyal Health integration risk following 2026-06-04 acquisition could strain resources during leadership transition.
- Generalist AI copilots from Innovaccer and others commoditizing the analytics layer Clarify built its moat on.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Innovaccer | losing to | Raised $275M Series F at ~$3.45B valuation Jan 2025, serves 7 of top 10 US health systems vs Clarify's ~$0.2B mid-2026 estimate |
| Epic Systems | contesting | Holds ~35%+ US hospital EHR share; lacks Clarify's cross-payer claims data but dominates workflow surface |
| Health Catalyst | contesting | Public rival (NASDAQ: HCAT) competing directly in healthcare analytics, traded ~$2.06/share as of 2026-07-22 |
| Oracle Health | contesting | Oracle, Cleveland Clinic, G42 announced AI healthcare delivery platform partnership 2025-05-16 |
Questions people ask
- Is Clarify Health profitable in 2026?
- No public profitability data exists. Revenue estimates for 2026 vary wildly across trackers, from about $25.3 million (StartupHub, 2026-07-01) to $52.5 million (Datanyze) to prior-year PrivCo estimates of $380 million for 2024, indicating no confirmed public figure and likely a shrinking business.
- Is Clarify Health being sold or acquired?
- Axios reported on 2025-05-27 that Clarify was working with Barclays on a potential sale. As of mid-2026 no confirmed sale outcome has surfaced; instead Clarify itself acquired Loyal Health Holdings on 2026-06-04, suggesting the sale process stalled or pivoted.
- Who is Clarify Health's biggest competitor?
- Innovaccer is the biggest threat, having raised a $275 million Series F in January 2025 at roughly a $3.45 billion valuation and serving 7 of the top 10 US health systems, dwarfing Clarify's mid-2026 secondary-market valuation estimate of about $0.2 billion.
- Could AI replace Clarify Health's analytics products?
- Much of Clarify's structured-data analytics work is exposed to commoditization; rival Innovaccer's Population Health Copilot reportedly cuts analyst effort 40-80% per an AWS case study (2026-04-14, vendor-claimed). Clarify's defense is proprietary claims data and workflow lock-in across 60+ health systems, not the analytics layer itself.
- How much is Clarify Health worth now versus its 2022 peak?
- Clarify raised a $150 million Series D in April 2022 valuing it at $1.4 billion. A mid-2026 secondary-market estimate (TrueUp, 2026-06-30) put its implied valuation near $0.2 billion, about an 86 percent decline, though this is a secondary estimate, not a primary transaction.
- Who owns Clarify Health?
- Clarify Health Solutions is privately held, backed by KKR, SoftBank Vision Fund 2, Insight Partners, Spark Capital, Concord Health Partners, and Hummer Winblad Venture Partners, following a $150 million Series D closed 2022-04-05 led by SoftBank with KKR participation.
Timeline
- 2026-06-04Clarify Health acquires Loyal Health Holdings, patient activation platform with 500+ hospital clients
- 2026-05-01Co-founder Todd Gottula named CEO, replacing Jean Drouin
- 2026-02-11Clarify publishes brief on CMS TEAM bundled-payment model covering 741 hospitals, 188 markets
- 2025-05-27Axios reports Clarify working with Barclays on a potential sale
- 2025-01Rival Innovaccer raises $275M Series F at ~$3.45B valuation
- 2022-04-05Clarify closes $150M Series D led by SoftBank, valuing company at $1.4B
- 2015Clarify Health founded in San Francisco by Jean Drouin, Todd Gottula, Todd Lee
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Clarify Health Reaches $1.4 Billion Value in SoftBank Vision Fund-Led Round (2022-04-05)
- Clarify Health Closes $150M Series D Funding (2022-04-05)
- Clarify Health Stock Price, Funding, Valuation, Revenue & Financial Statements (2026-06-03)
- Company Profile (2026-06-30)
- Clarify Health working with Barclays on sale (2025-05-27)
- Clarify Health Names Co-Founder Todd Gottula CEO (2026-05-01)
- Clarify Health Solutions, Inc. Company Profile
- Revenue, Competitors, Alternatives (2022-03-30)
- Clarify Health - HealthTech - Reviews & Alternatives (2026-07-01)
- Management and Employees List
- Transform Healthcare Outcomes Today, Clarify Health
- Optimize Referrals Today, Drive Outcomes